The Effect of Fluoxetine on Amblyopia Treatment

Effect of fluoxetine on visual acuity and VEP indices in amblyopia patients over 18 years of age

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180316039110N1

Enrollment

Registered

2018-06-05

Start date

2016-09-22

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amblyopia. Strabismic amblyopia, bilateral

Interventions

Intervention 1: Intervention group: Fluoxetine 20 mg. Intervention 2: Control group: Placebo.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who had at least one line difference between two eyes and have vision should be 20/25 or better age above 18 years Patients with anisometropic or strabismic amblyopia

Exclusion criteria

Exclusion criteria: Any eye disorder (cornea and retina, etc.) Patients who do not cooperate with VEP History of seizure History of bipolar disorder History of current or current use of SSRI or SNRI drugs Patients who do not go to follow up people under the age of 18

Design outcomes

Primary

Measure	Time frame
BCVA. Timepoint: Every month for 90 days. Method of measurement: Based on the chart.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArash Mir Mohammad Sadeghi

Tehran University of Medical Sciences

ammsadeghi@sina.tums.ac.ir+98 912 792 7992

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026